Study comparing single-agent olaparib or in combination with cediranib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

What we are studying

The purpose of this study is to compare the effect on cancer of using either olaparib by itself or the combination of cediranib and olaparib to the usual chemotherapy given for cancer (carboplatin and paclitaxel; carboplatin and gemcitabine; or carboplatin and pegylated liposomal doxorubicin [PLD]). Any of these different approaches could shrink cancer but could also cause side effects. This study will allow the researchers to learn whether giving olaparib by itself or giving the combination of cediranib and olaparib is better, the same, or worse than the usual chemotherapy by observing both the effect of these treatments on cancer as well as any side effects that may be experienced.

Who is Eligible

  • Genders:
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian primary peritoneal or fallopian tube cancers

What is involved

  • Study medication


Parking will be validated for study-related visits.

Contact Information

Study Coordinator
Melissa Swain
[email protected]
Principal Investigator
Samuel Lentz, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.